Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified vs Standard EC-MPS in Renal Transplant
NCT00369278Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2006
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mycophenolate sodium in kidney transplant rejection (2 arms), sponsored by Novartis. Primary endpoints: Time to First Occurrence of a Mycophenolic Acid (MPA) Plasma Concentration of ≥ 40 mg*h/L at Day 84, Time to First Occurrence of Any Treatment Failure During the First 6 Months Post-treatment or at Month 6 Post-treatment and 1 more. Started Jun 2006; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00369278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369278.